Stock Price Forecast

March 14, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Merus N.V chart...

About the Company

merus is developing best-in-class therapeutics to treat and potentially cure cancer patients. our most advanced development programs use the biclonics® format. biclonics® are capable of simultaneously attacking tumors in multiple ways. for example by activating the immune system to kill tumor cells and directly inhibiting tumor cell growth and survival pathways.

CEO

Sven Lundberg

Exchange

NASDAQ

Website

https://www.merus.nl/

$43M

Total Revenue

202

Employees

$3B

Market Capitalization

-17.44

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $MRUS News

Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business Update

19d ago, source: Business Insider

Feb. 28, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies ...

Gilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers

12d ago, source:

Gilead Sciences, Inc. (Nasdaq:GILD) and Merus N.V. (Nasdaq:MRUS) today announced a research collaboration, option and license ...

Merus: Positive Zenocutuzumab Data In 2024 Could Provide BLA Advancement

17d ago, source: Seeking Alpha

Merus N.V. (NASDAQ:MRUS) is definitely a biotech to keep an eye on in the 1st half of 2024. That's because there are two potential catalysts that, I believe, could cause its stock price to trade ...

Merus NV (2GH.DU)

3d ago, source: Yahoo Finance

Merus ( NASDAQ:MRUS ) Full Year 2023 Results Key Financial Results Revenue: US$43.9m (up 5.7% from FY 2022). Net loss... Simply Wall St. Earnings Update: Merus N.V. (NASDAQ:MRUS) Just Reported And ...

Merus to Participate in a Fireside Chat at the Leerink Partners Global Biopharma Conference

14d ago, source:

UTRECHT, The Netherlands and CAMBRIDGE, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: MRUS), a clinical-stage oncology ...

BMO lifts Merus shares price target to $58 on clinical data confidence

18d ago, source: Investing

Thursday - BMO Capital Markets has updated its outlook on Merus N.V. (NASDAQ:MRUS), increasing the price target to $58 from the previous $49 while maintaining an Outperform rating. This adjustment ...

Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business Update

19d ago, source: Yahoo Finance

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology ...

Gilead Sciences, Merus collaborate to discover novel antibody-based trispecific T-cell engagers

11d ago, source: Daily

Gilead Sciences, Inc. and Merus N.V. have announced a research collaboration, option and license agreement to discover novel ...

Merus to Participate in a Fireside Chat at the Leerink Partners Global Biopharma Conference

15d ago, source: ADVFN

Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg ...

Merus N.V.: Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business Update

19d ago, source: Finanznachrichten

Feb. 28, 2024(Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today ...

Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business Update

19d ago, source:

Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...